Catalent Biologics Content

  1. Comparing Batch Versus Continuous Modes 6/10/2019

    This case study compares the productivity of purifications running in batch versus continuous mode. Both Protein A capture resins demonstrated increased productivity with lower buffer volume in continuous mode.

  2. A Novel Purification Tool's Effects On HCP Reduction, Turbidity 6/10/2019

    This study involved a DoE approach to investigate effects of pH and conductivity on the turbidity, yield, and impurity clearance of the Emphaze™ AEX Hybrid Purifier and efficiency of the Protein A capture step.

  3. High-Throughput Formulation Development For High-Concentration mAbs 6/10/2019

    How a high-throughput, microwell plate platform can be used to economically screen a model IgG1 mAb at 120 mg/ml in 96 formulations while minimizing protein consumed and generating large amount of data.

  4. Strategies For Process Characterization, Late Phase Development 6/10/2019

    We propose a stepwise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody to improve the efficiency and effectiveness of the process.

  5. Achieving Unique Synergies In Antibody Expression 6/10/2019

    This poster demonstrates how a cell line development technology combined with a platform for cell line selection shortens timelines and generates productive, stable, high expressing cell lines.

  6. Transitioning From Vial To Prefilled Syringe

    Understand how formulation development for a prefilled syringe affects manufacturing, driving the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

  7. Overcoming Formulation Challenges For mRNA, High-Concentration Proteins

    Increased demand for protein delivery and the emergence of advanced modalities – including mRNA – are introducing new challenges to the development lifecycle, such as high-concentration formulations.

  8. Get Your Biologic To Clinic And Market Faster

    We are your one integrated partner with the expertise to get your therapeutic product to market faster, helping you accelerate, simplify, and de-risk your biologics.

  9. Biopharma 4.0 – Digital Transformation In The Biopharma Industry

    Biopharma 4.0 advances include the widespread automation of business processes within a company, comprehensive data integration, and interoperability between manufacturing and operations.

  10. The GPEx Suite Of Technologies For Cell Line Development

    Biopharma products in development continue to increase in complexity, which poses a challenge for pharmaceutical companies looking to improve speed and efficiency of biologic development.